Investigational drug · Phase 3
QLS32015
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "QLS32015"
First trial start
2025
Sep 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QLS32015", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "QLS32015" as an intervention, largest first.
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07138209 · 228 participants (planned) · Start Nov 7, 2025 · Primary completion Dec 2027
Drug: QLS32015; Pomalidomide and 2 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Tianjin, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT07018050 · 160 participants (planned) · Start Sep 12, 2025 · Primary completion Nov 2027
Drug: QLS32015; Pomalidomide and 4 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Tianjin, China
Qilu Pharmaceutical Co., Ltd.Industry
NCT05920876 · 100 participants (planned) · Start Jun 30, 2023 · Primary completion Dec 31, 2024
Drug: QLS32015 · For: Relapsed or Refractory Multiple Myeloma
Sites: Tianjin, China
- A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple MyelomaNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07185477 · 20 participants (planned) · Start Sep 15, 2025 · Primary completion May 31, 2027
Drug: QLS32015 · For: Relapsed/Refractory Multiple Myeloma (RRMM)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Relapsed or Refractory Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- QLS4131Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma
- MBS314Phase 22 trials
Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma
- AZD4045Phase 21 trial
AstraZeneca · Relapsed or Refractory Multiple Myeloma
- CD38Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
- F182112Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.